Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

G Li, E De Clercq - Nature reviews Drug discovery, 2020 - nature.com
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we
discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection …

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

…, P Herdewijn, J Desmyter, E De Clercq - Journal of virological …, 1988 - Elsevier
A rapid, sensitive and automated assay procedure was developed for the in vitro evaluation
of anti-HIV agents. An HTLV-I transformed T4-cell line, MT-4, which was previously shown …

Antiviral drugs in current clinical use

E De Clercq - Journal of clinical virology, 2004 - Elsevier
… Other main hydrophobic contacts are shown with bold lines; minor ones are shown with
faint lines (after De Clercq, 2002a). … E De ClercqE De Clercq

Strategies in the design of antiviral drugs

E De Clercq - Nature Reviews drug discovery, 2002 - nature.com
… Balzarini, J., Hao, Z., Herdewijn, P., Johns, DG & De Clercq, E. Intracellular metabolism
and … De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus …

Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus …

…, R Snoeck, R Pauwels, E De Clercq - Antimicrobial agents and …, 1988 - Am Soc Microbiol
… Desmyter, and E. De Clercq. 1988. Mechanism of inhibitory effect of dextran sulfate and
heparin on replication … De Clercq, E. 1985. Antiviral and antimetabolic activities of neplanocins. …

Approved antiviral drugs over the past 50 years

E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
… activity of (S)-DHPA was first reported by De Clercq et al. (257), shortly after acyclovir had …
as a new broad-spectrum anti-DNA virus agent by De Clercq et al. (258). Although (S)-HPMPA …

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

…, GP Allaway, TP Sakmar, G Henson, E DeClercq… - Nature medicine, 1998 - nature.com
… , Canada V2V 1N5 Correspondence should be addressed to: JPM; e-mail: jmoore&adarc.org …
& De Clercq, E. Bicyclams, a class of potent antiHIV agents, are targeted at the HIV …

CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity

…, L Brambilla, R Galli, D Schols, E De Clercq… - Nature …, 2001 - nature.com
Astrocytes actively participate in synaptic integration by releasing transmitter (glutamate) via
a calcium-regulated, exocytosis-like process. Here we show that this process follows …

Angiogenesis: regulators and clinical applications

S Liekens, E De Clercq, J Neyts - Biochemical pharmacology, 2001 - Elsevier
1 Angiogenesis is a fundamental process in reproduction and wound healing. Under these
conditions, neovascularization is tightly regulated. Unregulated angiogenesis may lead to …

[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to
develop therapeutic strategies that target severe acute respiratory syndrome coronavirus 2 (…